What is Blue Biotechnology Market?
Blue biotechnology also known as blue biotech, includes biological materials that originate from the aquatic environment, freshwater, and marine. Blue biotechnology is increasingly seen as a technical and commercially realistic direction of development and is a major sector of interest particularly in North America and the European Union. The blue biotechnology encourages the use of marine bioresources as the source of the biotechnological application. Increasing demand for organic cosmetics due to the side effects of synthetic makeup will supplement the market growth in the forecast period.
The market study is being classified by Type (Enzymes, Pharma Products, Bulk Chemicals and Biopolymers), by Application (Bio-Engineering, Genomics, Vaccine Development, Drug Discovery and Others) and major geographies with country level break-up.
Sea Run Holdings, Inc.(United States), PICES (Canada), Donald Danforth Plant Science Center (United States), Shell Marine Products (United States), Aker BioMarine (Norway), Marinova (Australia), New England Biolabs (United States), PML Applications Ltd. (United Kingdom), GeoMarine Biotechnologies (India) and GlycoMar (Scotland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Aker BioMarins (Norway), Samudra Biopharma Pvt. Ltd (India), Sanosil Biotech (India), Cellgen Biologicals Pvt Ltd. (India) and Nurture Aqua Technology Pvt. Ltd. (India).
Global blue biotechnology market consists of few established players accounting for the major market shares. To date, however, only one percent of biotech companies are engaged in blue biotechnology. The entry of private-labels in the market is expected to increase the competition levels in forecast years.
Segment Analysis
Analyst at AMA have segmented the market study of Global Blue Biotechnology market by Type, Application and Region.
On the basis of geography, the market of Blue Biotechnology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Growing Issues Of Food Security And Water Availability
- Ageing Population In Developed Economies
Market Trend
- Microalgae Incorporation Into Innovative Food Products
Restraints
- Lack Of Awareness About The Usage Of Marine Microorganism
Opportunities
- Growing Demand Of Aquatic Biotechnology In Cosmetics Industry
- Ongoing Research & Development In Blue Biotechnology
Challenges
- Stringent Regulations For Marine And Aquatic Ecosystem
In July 2019, Archer Daniels Midland Company launched OnavitaAlgal DHA and AlmegaEPA blends via collaboration with Qualitas Health, a leader in algae cultivation. These products contains omega-3, 6 and 9
By 2020 European Union will develop and apply advanced tools, platforms and infrastructures and support to Marine Biotechnology to provide a significant contribution to addressing key societal challenges of the next decades in the areas of food and energy, development of novel drugs and treatments for human health and the sustainable use and management of the seas and oceans.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Blue Biotechnology Providers, Venture Capitalists and Private Equity Firms, Government Regulatory, Research Organizations and End Use Industry
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase